Wells Fargo & Company MN Grows Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Wells Fargo & Company MN boosted its holdings in Amedisys, Inc. (NASDAQ:AMED) by 4.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,161 shares of the health services provider’s stock after buying an additional 323 shares during the period. Wells Fargo & Company MN’s holdings in Amedisys were worth $650,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of AMED. Barclays PLC raised its stake in Amedisys by 49.5% during the 3rd quarter. Barclays PLC now owns 15,529 shares of the health services provider’s stock valued at $1,500,000 after purchasing an additional 5,142 shares during the period. Versant Capital Management Inc grew its holdings in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares in the last quarter. HBW Advisory Services LLC bought a new stake in shares of Amedisys during the fourth quarter valued at approximately $38,000. Oak Thistle LLC lifted its holdings in shares of Amedisys by 97.6% in the fourth quarter. Oak Thistle LLC now owns 6,964 shares of the health services provider’s stock worth $632,000 after buying an additional 3,440 shares in the last quarter. Finally, Ballentine Partners LLC bought a new position in shares of Amedisys during the fourth quarter worth $334,000. 94.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

AMED has been the topic of a number of research reports. Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $100.75.

Amedisys Price Performance

AMED stock opened at $95.20 on Friday. The company has a fifty day simple moving average of $92.49 and a two-hundred day simple moving average of $91.77. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $3.12 billion, a P/E ratio of 37.78, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. During the same quarter last year, the firm earned $1.03 EPS. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. Analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.